Novartis PTK/ZK 787 Data Presented At ASCO; Survival Analysis Pending
Executive Summary
Further development of Novartis/Schering AG's colorectal cancer agent PTK/ZK 787 (vatalanib) should include optimizing the dosing schedule and identifying appropriate prognostic factors, a consultant suggested at the American Society of Clinical Oncology annual meeting